← back to search

Jinpu Yu

Tianjin Medical University Cancer Institute and Hospital · CN
Area of research
Immunology · Oncology
Research interest
Research interests include Immune Cell Function and Interaction, Immune cells in cancer, Cancer Immunotherapy and Biomarkers, and Immunotherapy and Immune Responses.
h-index
41
citations
5,874
works
240
NIH funding
primary concept
Medicine
email

Recent publications

Expert Consensus on the Diagnosis and Treatment of Malignant Mesothelioma of the Tunica Vaginalis Testis
iMetaMed 2025cited by 3position: middledoi
POS1166 EFFICACY AND SAFETY OF GENAKUMAB FOR FIRST-LINE TREATMENT OF GOUT FLARE: A PHASE 2, MULTICENTER, OPEN-LABEL, ACTIVE CONTROLLED, RANDOMIZED NON-INFERIORITY TRIAL
Annals of the Rheumatic Diseases 2025cited by 1position: middledoi
Recent advances and clinical prospects of non-viral brain-targeted gene delivery systems
Applied Physics Reviews 2025cited by 1position: contributordoi
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
Cancer Cell 2024cited by 45position: middledoi
Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors
Global Medical Genetics 2024cited by 14position: middledoi
Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors
Global Medical Genetics 2024cited by 7position: middledoi
Optical Genome Mapping Reveals the Landscape of Structural Variations and Their Clinical Significance in HBOC-Related Breast Cancer
Frontiers in Bioscience-Landmark 2024cited by 6position: lastdoi
Preliminary exploration of poor prognostic factor IL-33 and its involvement in perioperative immunotherapy in stage II-III lung squamous cell carcinoma: a retrospective cohort study.
2024cited by 0position: contributordoi
Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC.
2023cited by 57position: contributordoi
Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma
Thoracic Cancer 2023cited by 19position: middledoi
Expert consensus on the diagnosis and treatment of <scp>RET</scp> gene fusion <scp>non‐small</scp> cell lung cancer in <scp>China</scp>
Thoracic Cancer 2023cited by 12position: middledoi
Figure S6 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Data from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S5 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S2 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S3 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S2 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S4 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S5 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S6 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Supplemental tables from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S3 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S1 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Data from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S4 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Supplemental tables from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Figure S1 from LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY
2023cited by 0position: contributordoi
Chinese expert consensus on the diagnosis and treatment of <scp>HER2</scp>‐altered non–small cell lung cancer
Thoracic Cancer 2022cited by 17position: middledoi
Expert consensus on the diagnosis and treatment of <scp><i>NTRK</i></scp> gene fusion solid tumors in China
Thoracic Cancer 2022cited by 17position: middledoi
Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness
Molecular Therapy 2021cited by 79position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 21 papers (2019–2025)Hui Li · University of Maryland, Baltimore2 papers (2014–2017)Shuaibing Wang · Beijing Jiaotong University1 papers (2020–2020) · 1 papers (2024–2024)Shizhen Emily Wang · University of California San Diego1 papers (2017–2017)Jie Ma · Harbin Medical University1 papers (2020–2020)Ya‐Jung Cheng · National Taiwan University1 papers (2013–2013)Xiaoliang Shi · Zhejiang University1 papers (2020–2020)Lili Yang · Army Medical University1 papers (2017–2017)Jun Liu · Guangzhou University of Chinese Medicine1 papers (2014–2014)Feng Cao · Anhui Medical University1 papers (2013–2013) · 1 papers (2020–2020)Runmei Li · Guangzhou University of Chinese Medicine1 papers (2017–2017)Xiaojing Guo · Tianjin Medical University Cancer Institute and Hospital1 papers (2024–2024)Feng Wei · Hebei Medical University1 papers (2017–2017)Jin Wang · Tianjin Medical University1 papers (2013–2013)Wenwen Yu · Nanjing Agricultural University1 papers (2014–2014) · 1 papers (2020–2020)Shujing Long · Hebei Medical University1 papers (2013–2013)Yuqing Wang · Hebei Medical University1 papers (2013–2013)